Drug Trial Radar · NCT06214156
A Clinical Study of T3011 in Subjects With Advanced Melanoma
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Jan 26, 2024
Primary completion
Sep 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study evaluated the tolerability, safety and preliminary efficacy of T3011 in subjects with advanced melanoma.
Conditions
- Advanced Melanoma
Interventions
T3011Biological
T3011 will be given intratumorally, Q2W;
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: Approximately 2 years
- Objective response rate(ORR)Time frame: Approximately 2 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China · Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China · Recruiting
Jilin Cancer Hospital
Changchun, China · Recruiting
Chengdu Shangjin Nanfu Hospital
Chengdu, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
The Third People's Hospital of Zhengzhou
Zhengzhou, China · Recruiting
Sun Yat-sen University Cancer Center
Zhongshan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.